JP2023526332A - 特定の化学組成物およびその使用方法 - Google Patents

特定の化学組成物およびその使用方法 Download PDF

Info

Publication number
JP2023526332A
JP2023526332A JP2022569528A JP2022569528A JP2023526332A JP 2023526332 A JP2023526332 A JP 2023526332A JP 2022569528 A JP2022569528 A JP 2022569528A JP 2022569528 A JP2022569528 A JP 2022569528A JP 2023526332 A JP2023526332 A JP 2023526332A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
amino
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526332A5 (https=
Inventor
ダブリュー． コンラーディ，アンドレイ
ヒュアン，チュン－ハオ
リー，コー－チュアン
Original Assignee
アルゲン バイオテクノロジーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゲン バイオテクノロジーズ，インク． filed Critical アルゲン バイオテクノロジーズ，インク．
Publication of JP2023526332A publication Critical patent/JP2023526332A/ja
Publication of JP2023526332A5 publication Critical patent/JP2023526332A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022569528A 2020-05-15 2021-05-14 特定の化学組成物およびその使用方法 Pending JP2023526332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025474P 2020-05-15 2020-05-15
US63/025,474 2020-05-15
PCT/US2021/032495 WO2021231892A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023526332A true JP2023526332A (ja) 2023-06-21
JP2023526332A5 JP2023526332A5 (https=) 2024-05-10

Family

ID=76270111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569528A Pending JP2023526332A (ja) 2020-05-15 2021-05-14 特定の化学組成物およびその使用方法

Country Status (12)

Country Link
US (2) US11591322B2 (https=)
EP (1) EP4149941B1 (https=)
JP (1) JP2023526332A (https=)
KR (1) KR20230051127A (https=)
CN (1) CN116261561B (https=)
AU (1) AU2021273072A1 (https=)
BR (1) BR112022023199A2 (https=)
CA (1) CA3178813A1 (https=)
ES (1) ES3054109T3 (https=)
IL (1) IL298219A (https=)
MX (1) MX2022014356A (https=)
WO (1) WO2021231892A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
WO2023086417A1 (en) * 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500311A (ja) * 2009-07-30 2013-01-07 ノバルティス アーゲー タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体
JP2014506878A (ja) * 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP1223952B1 (en) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2012101065A2 (en) * 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
EP3874045A4 (en) 2018-10-31 2022-09-07 The Regents of The University of California Methods and kits for identifying cancer treatment targets
CN114025772A (zh) 2019-04-24 2022-02-08 纪念斯隆凯特琳癌症中心 用于治疗ras突变体癌症的组合物和方法
JP7677914B2 (ja) 2019-06-21 2025-05-15 アルゲン バイオテクノロジーズ，インク． 標的遺伝子を特定するための方法およびシステム
EP4126918A4 (en) 2020-03-31 2024-05-29 The Regents of the University of California COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR THE TREATMENT OF RNA VIRUS INFECTIONS
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
EP4185867A4 (en) 2020-07-22 2024-08-07 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness
WO2023086417A1 (en) 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500311A (ja) * 2009-07-30 2013-01-07 ノバルティス アーゲー タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体
JP2014506878A (ja) * 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用

Also Published As

Publication number Publication date
CN116261561A (zh) 2023-06-13
US20220289725A1 (en) 2022-09-15
US20230295135A1 (en) 2023-09-21
EP4149941A1 (en) 2023-03-22
CA3178813A1 (en) 2021-11-18
US12264152B2 (en) 2025-04-01
AU2021273072A1 (en) 2022-12-15
BR112022023199A2 (pt) 2023-04-04
KR20230051127A (ko) 2023-04-17
ES3054109T3 (en) 2026-01-29
IL298219A (en) 2023-01-01
US11591322B2 (en) 2023-02-28
CN116261561B (zh) 2025-10-31
MX2022014356A (es) 2023-03-09
WO2021231892A1 (en) 2021-11-18
EP4149941B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
JP6468611B2 (ja) キナーゼ阻害のためのヘテロアリール化合物
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
JP7015059B2 (ja) 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
ES2664794T3 (es) Inhibidores de ERK y métodos de uso
KR20230142504A (ko) Cdk 억제제
JP6863901B2 (ja) キナーゼ阻害のためのヘテロアリール化合物
JP2019194217A (ja) キナーゼ阻害のためのヘテロアリール化合物
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
EP4165035A1 (en) Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2023279041A1 (en) Indazole compounds
CN120699028A (zh) Nek7激酶的抑制剂
JP2023538304A (ja) 化合物、組成物及び方法
RU2747311C2 (ru) Ингибитор CDK4/6
JP2024537110A (ja) Ｅｎｔ１阻害活性を有する大環状化合物
US12264152B2 (en) Certain chemical compositions and methods of use thereof
TW202010500A (zh) 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US20210346405A1 (en) Bcl-2 inhibitors and their use as pharmaceuticals
US20140343052A1 (en) Phenylxanthene Derivatives
WO2023086417A1 (en) Compounds and methods of use thereof
RU2799047C2 (ru) Ингибитор atr и его применение
WO2024216249A1 (en) Cdk inhibitors and their use as pharmaceuticals
BR112020001124B1 (pt) Composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e uso do composto ou do sal farmaceuticamente aceitável do mesmo
BR112019012176B1 (pt) Compostos inibidores de cdk4/6 ou seus sais, composição farmacêutica os compreendendo e uso dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260420